TGFB1 and neoplasm: Notably, transforming growth factor-beta (TGF-β), abundantly present in the tumor microenvironment, downregulates the expression of key NK cell–activating receptors such as NKG2D and NKp30, thereby compromising tumor cell recognition and cytolytic function (32–36).